Coriolis Pharma Research GmbH

Coriolis is a world-leading independent contract research and development organisation specialised in BIOPHARMACEUTICAL FORMULATION and DRUG PRODUCT DEVELOPMENT, including LYOPHILISATION PROCESSES and ANALYTICAL DEVELOPMENT for proteins, peptides, monoclonal antibodies, RNA/DNA, etc., as well as vaccines. This contains highly concentrated protein formulations or developments for subcutaneous administrations or other complex formulations. Besides others,

Coriolis also offers as standalone services GMP-COMP-

LIANT ANALYTICS for subvisible particle analysis and aggregation characterisation (e.g. light obscuration (LO), flow imaging microscopy (MFI), asymmetrical flow field-flow fractionation (AF4)), and other innovative techniques. Most recently we also offer

POLYSORBATE ANALYTICS such as quantification and characterisation of degradation products.

Coriolis is specialised in the provision of:

› Formulation development services for liquid and lyophilised products covering pre-formulation and candidate selection, early stage formulation development, late phase formulation development, lyophilisation cycle optimization and scale-up and transfer studies. › Support in container closure system selection › In-use stability studies › Stability testing including forced degradation studies › R&D and GMP-compliant contract analytical services › Orthogonal analysis of subvisible aggregates and particles › Testing of S1 and S2 GMO material › Polysorbate analytics › Outstanding scientific expertise

  • Ausrichtungen
    • Auftragsforschung
  • Gegründet

    2008
  • Aktualisiert am

    25.07.2019